180 related articles for article (PubMed ID: 24118434)
1. Interaction of disulfiram with antiretroviral medications: efavirenz increases while atazanavir decreases disulfiram effect on enzymes of alcohol metabolism.
McCance-Katz EF; Gruber VA; Beatty G; Lum P; Ma Q; DiFrancesco R; Hochreiter J; Wallace PK; Faiman MD; Morse GD
Am J Addict; 2014; 23(2):137-44. PubMed ID: 24118434
[TBL] [Abstract][Full Text] [Related]
2. Impact of ritonavir, atazanavir and their combination on the CYP3A4 induction potential of efavirenz in primary human hepatocytes.
Mugundu GM; Hariparsad N; Desai PB
Drug Metab Lett; 2010 Jan; 4(1):45-50. PubMed ID: 20201776
[TBL] [Abstract][Full Text] [Related]
3. S-methyl-N,N-diethylthiocarbamate sulfoxide and S-methyl-N,N-diethylthiocarbamate sulfone, two candidates for the active metabolite of disulfiram.
Mays DC; Nelson AN; Lam-Holt J; Fauq AH; Lipsky JJ
Alcohol Clin Exp Res; 1996 May; 20(3):595-600. PubMed ID: 8727261
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study.
Dumond JB; Adams JL; Prince HM; Kendrick RL; Wang R; Jennings SH; Malone S; White N; Sykes C; Corbett AH; Patterson KB; Forrest A; Kashuba AD
HIV Med; 2013 Aug; 14(7):401-9. PubMed ID: 23433482
[TBL] [Abstract][Full Text] [Related]
5. The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients.
Josephson F; Andersson MC; Flamholc L; Gisslén M; Hagberg L; Ormaasen V; Sönnerborg A; Vesterbacka J; Böttiger Y
Eur J Clin Pharmacol; 2010 Apr; 66(4):349-57. PubMed ID: 19967342
[TBL] [Abstract][Full Text] [Related]
6. Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir.
Bifano M; Hwang C; Oosterhuis B; Hartstra J; Grasela D; Tiessen R; Velinova-Donga M; Kandoussi H; Sevinsky H; Bertz R
Antivir Ther; 2013; 18(7):931-40. PubMed ID: 23963204
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic interactions of CEP-1347 and atazanavir in HIV-infected patients.
Ma Q; Gelbard HA; Maggirwar SB; Dewhurst S; Gendelman HE; Peterson DR; DiFrancesco R; Hochreiter JS; Morse GD; Schifitto G
J Neurovirol; 2013 Jun; 19(3):254-60. PubMed ID: 23737347
[TBL] [Abstract][Full Text] [Related]
8. Population Pharmacokinetics Modeling of Unbound Efavirenz, Atazanavir, and Ritonavir in HIV-Infected Subjects With Aging Biomarkers.
Dumond JB; Chen J; Cottrell M; Trezza CR; Prince H; Sykes C; Torrice C; White N; Malone S; Wang R; Patterson KB; Sharpless NE; Forrest A
CPT Pharmacometrics Syst Pharmacol; 2017 Feb; 6(2):128-135. PubMed ID: 28032946
[TBL] [Abstract][Full Text] [Related]
9. Effects of oral posaconazole on the pharmacokinetics of atazanavir alone and with ritonavir or with efavirenz in healthy adult volunteers.
Krishna G; Moton A; Ma L; Martinho M; Seiberling M; McLeod J
J Acquir Immune Defic Syndr; 2009 Aug; 51(4):437-44. PubMed ID: 19623694
[TBL] [Abstract][Full Text] [Related]
10. In vivo pharmacodynamic studies of the disulfiram metabolite S-methyl N,N-diethylthiolcarbamate sulfoxide: inhibition of liver aldehyde dehydrogenase.
Hart BW; Faiman MD
Alcohol Clin Exp Res; 1994 Apr; 18(2):340-5. PubMed ID: 8048736
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo inhibition of rat liver aldehyde dehydrogenase by S-methyl N,N-diethylthiolcarbamate sulfoxide, a new metabolite of disulfiram.
Hart BW; Faiman MD
Biochem Pharmacol; 1992 Feb; 43(3):403-6. PubMed ID: 1311578
[TBL] [Abstract][Full Text] [Related]
12. S-methyl-N,N-diethylthiolcarbamate: a disulfiram metabolite and potent rat liver mitochondrial low Km aldehyde dehydrogenase inhibitor.
Hart BW; Yourick JJ; Faiman MD
Alcohol; 1990; 7(2):165-9. PubMed ID: 2158327
[TBL] [Abstract][Full Text] [Related]
13. Bioactivation of S-methyl N,N-diethylthiolcarbamate to S-methyl N,N-diethylthiolcarbamate sulfoxide. Implications for the role of cytochrome P450.
Hart BW; Faiman MD
Biochem Pharmacol; 1993 Dec; 46(12):2285-90. PubMed ID: 8274162
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status.
Mollan K; Daar ES; Sax PE; Balamane M; Collier AC; Fischl MA; Lalama CM; Bosch RJ; Tierney C; Katzenstein D;
J Infect Dis; 2012 Dec; 206(12):1920-30. PubMed ID: 23148287
[TBL] [Abstract][Full Text] [Related]
15. Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir.
Pham PA; Flexner C; Parsons T; Vasist L; Fuchs E; Carson K; Agarwala S; Barditch-Crovo P
J Acquir Immune Defic Syndr; 2007 Jun; 45(2):201-5. PubMed ID: 17414932
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies.
Schipani A; Dickinson L; Boffito M; Austin R; Owen A; Back D; Khoo S; Davies G
J Acquir Immune Defic Syndr; 2013 Jan; 62(1):60-6. PubMed ID: 23011396
[TBL] [Abstract][Full Text] [Related]
17. Disulfiram metabolism as a requirement for the inhibition of rat liver mitochondrial low Km aldehyde dehydrogenase.
Yourick JJ; Faiman MD
Biochem Pharmacol; 1991 Sep; 42(7):1361-6. PubMed ID: 1656985
[TBL] [Abstract][Full Text] [Related]
18. Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir.
McComsey GA; Kitch D; Daar ES; Tierney C; Jahed NC; Melbourne K; Ha B; Brown TT; Bloom A; Fedarko N; Sax PE
AIDS; 2012 Jul; 26(11):1371-85. PubMed ID: 22546988
[TBL] [Abstract][Full Text] [Related]
19. Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers.
Burger DM; Agarwala S; Child M; Been-Tiktak A; Wang Y; Bertz R
Antimicrob Agents Chemother; 2006 Oct; 50(10):3336-42. PubMed ID: 17005814
[TBL] [Abstract][Full Text] [Related]
20. Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach.
Siccardi M; Marzolini C; Seden K; Almond L; Kirov A; Khoo S; Owen A; Back D
Clin Pharmacokinet; 2013 Jul; 52(7):583-92. PubMed ID: 23479398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
